# OnCo record egfr (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/egfr/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "egfr" ;
  schema:name "EGFR"@en ;
  schema:description "A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills."@en ;
  schema:url <https://onco.cc/targets/egfr/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146648>, <https://www.uniprot.org/uniprotkb/P00533/entry>, <https://www.ncbi.nlm.nih.gov/gene/1956> ;
  owl:sameAs <http://www.wikidata.org/entity/Q424401> ;
  schema:citation <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor> ;
  onco:tag "driver", "kinase" ;
  schema:alternateName "EGFR" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1984"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-l858r/>, <https://onco.cc/biomarkers/egfr-exon-20-insertion/>, <https://onco.cc/biomarkers/egfr-t790m/>, <https://onco.cc/biomarkers/egfr-c797s/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:drugs <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/mobocertinib/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/necitumumab/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/drugs/jmt101/>, <https://onco.cc/drugs/hs-20117/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/tqb6411/>, <https://onco.cc/drugs/tqb2930/>, <https://onco.cc/drugs/tqb2922/>, <https://onco.cc/drugs/e-edv-d682/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/silevertinib/>, <https://onco.cc/drugs/vrn110755/>, <https://onco.cc/drugs/js111/> ;
  onco:companies <https://onco.cc/companies/bicara-therapeutics/>, <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/inivata/>, <https://onco.cc/companies/lucence/>, <https://onco.cc/companies/oric-pharmaceuticals/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/breast-cancer-signalling/>, <https://onco.cc/pathways/choline-metabolism-in-cancer/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/glioma-signalling/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/prostate-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/wild-type/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-exon20-insertion/> ;
  onco:trials <https://onco.cc/trials/nct06043817/>, <https://onco.cc/trials/nct06567015/>, <https://onco.cc/trials/nct06975410/>, <https://onco.cc/trials/nct05394831/>, <https://onco.cc/trials/nct05168566/>, <https://onco.cc/trials/nct07467863/>, <https://onco.cc/trials/nct06080776/>, <https://onco.cc/trials/nct06616766/>, <https://onco.cc/trials/nct07136779/>, <https://onco.cc/trials/nct07641023/>, <https://onco.cc/trials/nct05920135/>, <https://onco.cc/trials/nct06940401/>, <https://onco.cc/trials/nct06010329/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/>, <https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/>, <https://onco.cc/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/>, <https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/>, <https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/>, <https://onco.cc/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/>, <https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/> .